News
Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
Encinitas, California--(August 16, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) welcomes investors to watch the Company's online presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference. As part of the talk, Kiora President & CEO Brian...
Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress
Positive Preliminary Data Reported in Q2 Demonstrated Clear Clinical Proof-of-Concept of KIO-301 in the Ongoing Phase 1 Study in Retinitis Pigmentosa Supporting Advancement to Planned Higher Doses with Full Topline Results Expected in Q4 2023Data Supports Hypothesized...
Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment
Encinitas, California--(August 3, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage ophthalmic pharmaceutical company developing novel therapeutics for patients with high unmet needs, and the Choroideremia Research Foundation (CRF), the largest...
Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals’ Board of Directors
Encinitas, California--(August 1, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) has appointed Carmine Stengone as an independent member to the Company's board of directors. Stengone currently serves as the President and CEO of Pipeline Therapeutics, a company...
Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease
Encinitas, California--(July 5, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its wholly owned subsidiaries have received, in aggregate, $1.2 million related to research tax incentives from the Austrian and Australian governments for research...
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
Amendment eliminates $4.75M in near-term milestones Kiora would have owed to SentrxSentrx gains access to Kiora's recently issued patents covering the combination of KIO-201 and antibiotics for veterinary useKiora will receive a royalty on net sales of products...
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences
Encinitas, California--(June 14, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its President & CEO, Brian Strem, Ph.D., will participate in two upcoming investor conferences. The Healthcare Virtual Conference hosted by Maxim GroupJune 20, 2023 from...
Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Encinitas, California--(June 6, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the closing of an underwritten public offering for gross proceeds of approximately $6.3 million, which includes full exercise of the...
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
Encinitas, California--(June 2, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the pricing of an underwritten public offering for gross proceeds of approximately $5.5 million prior to deducting underwriting discounts and...
Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments
Encinitas, California--(May 9, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) announced its first quarter 2023 results, during which time it significantly advanced its ocular drug development pipeline of clinical-stage candidates for the treatment of Retinitis...